title: Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
abstract: The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event. HIV associated Hodgkin's disease (HD) has also been observed. A unique patient with both entities is described. The patient was a 29 year old homosexual male who developed clinical IIA nodular sclerosis HD in 1985. He was HIV + with CD4/CD8 = 0.2 and his sister had HD 20 years earlier. He received MOPP and had a complete response. In October 1988 he developed weight loss with an abdominal mass and biopsy revealed diffuse small non-cleaved NHL, with bone marrow involvement. This was his first AIDS associated illness. Probes identified clonally rearranged DNA fragments in the J region of IgH chains and clonal rearrangements in the c-myc gene were also observed but EBV sequences could not be demonstrated. He was treated with m-BACOD but died in March 1989. His course was not complicated by opportunistic infection. Possible etiologies for the HD include his HIV status or shared sibling environment. The development of the NHL may have resulted from HIV infection and/or secondary to his treatment for HD. The relationship between the two lymphomas is uncertain and factors other than HIV exposure and its immune dysfunction may have been causal.
authors.affiliation: Don Monti Division of Oncology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York 11030.
authors.forename: S M
authors.initials: SM
authors.lastname: Lichtman
authors.forename: J
authors.initials: J
authors.lastname: Brody
authors.forename: M H
authors.initials: MH
authors.lastname: Kaplan
authors.forename: M
authors.initials: M
authors.lastname: Susin
authors.forename: P
authors.initials: P
authors.lastname: Koduru
authors.forename: J C
authors.initials: JC
authors.lastname: Goh
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000235:genetics; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004781:Environmental Exposure; D005260:Female; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D015658:HIV Infections / Q000150:complications*; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D006801:Humans; D015994:Incidence; D002955:Leucovorin / Q000008:administration & dosage; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004273:DNA, Neoplasm; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate